Holen Sie sich die Stockscreener-App
4.67
6.22%
-0.31
Handel nachbörslich:
4.73
0.06
+1.28%
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy - Investing.com
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk - TipRanks
Small cap wrap: 374Water, Ideal Power, Northstar Gold, Candel Therapeutics… - Proactive financial news
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances - Yahoo Finance
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - Bitget
Incannex Healthcare Inc. (NASDAQ: IXHL) officially announced that the company has completed the pricing of a registered direct offering with a total size of 10 million dollars. - Bitget
Tech Rally: Is Candel Therapeutics Inc stock suitable for long term investing2026 Momentum Check & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Candel Therapeutics (NASDAQ:CADL) Raised to Hold at Zacks Research - MarketBeat
Candel Therapeutics Presents New Data From Phase 3 Trial Of Aglatimagene Besadenovec In Localized Prostate Cancer - marketscreener.com
Candel Therapeutics Back On The Radar As Prostate And Lung Cancer Trial Catalysts Approach - RTTNews
Candel Therapeutics to present Phase 3 prostate cancer data at AUA 2026 - Proactive Investors
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - Bitget
Paradigm-shifting prostate cancer trial data to debut at AUA 2026 - Stock Titan
Gainers Report: How Candel Therapeutics Inc. stock compares to market leadersWeekly Market Report & Growth Focused Investment Plans - Naître et grandir
Moving Averages: Will Candel Therapeutics Inc. stock outperform Nasdaq indexJuly 2025 Selloffs & Smart Allocation Stock Tips - Naître et grandir
Candel Therapeutics (CADL) Projected to Post Earnings on Thursday - MarketBeat
Candel Therapeutics, Inc. showcases linoserpaturev immunotherapy progress in recurrent glioblastoma case - Traders Union
United StatesGoodwin Guides Candel Therapeutics On $100 Million Public Offering And $100 Millon Royalty Funding Agreement With RTW - Mondaq
CADL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Candel Therapeutics CEO to present progress on immunotherapies at TD Cowen Health Care Conference - Traders Union
New Candel Therapeutics hire gets 20,000 stock options at $5.25 - Stock Titan
CADL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Hedge Fund and Insider Trading News: David Tepper, Steve Cohen, Ray Dalio, Brevan Howard, Millennium Management, Citadel Investment Group, Candel Therapeutics Inc (CADL), Meta Platforms Inc (META), and More - Insider Monkey
Candel Therapeutics Insider Bought Shares Worth $2,999,996, According to a Recent SEC Filing - marketscreener.com
Paul Manning buys Candel Therapeutics (CADL) shares worth $3m - Investing.com
Paul Manning buys Candel Therapeutics (CADL) shares worth $3m By Investing.com - Investing.com Australia
Candel Therapeutics (NASDAQ:CADL) Director Paul Manning Purchases 550,458 Shares - MarketBeat
Director Paul B. Manning adds 550,458 Candel (NASDAQ: CADL) shares via revocable trust - Stock Titan
Candel Therapeutics, Inc. (CADL) Stock Analysis: Unveiling a 259% Potential Upside in Biotech - DirectorsTalk Interviews
Candel Therapeutics, Inc. unveils science behind CAN-2409 driving durable tumor immune response - Traders Union
Candel Therapeutics CEO to present at TD Cowen health care conference on March 3 - Proactive financial news
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston - Bitget
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston - The Manila Times
Candel Therapeutics CEO to speak at TD Cowen Boston conference - Stock Titan
Candel Therapeutics Announces Equity Offering to Fund CAN-2409 - TipRanks
Candel Therapeutics Prices 18.35M-Share Offering at $5.45, Expects ~$93.5M Net Proceeds - TradingView
Candel Therapeutics (NASDAQ: CADL) prices $100M common stock sale - Stock Titan
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Candel Therapeutics Faces Strategic Financial Moves Amidst Stock Offering - timothysykes.com
Candel Therapeutics Prices $100M Public Offering - Intellectia AI
Candel Therapeutics Faces Market Reaction Post-Secondary Offering - StocksToTrade
Candel Therapeutics’ Stock Offering Sees Market Reaction - timothysykes.com
Candel Therapeutics Prices $100 Million Share Offering - Intellectia AI
Candel Therapeutics Faces Mixed Sentiments After Secondary Offering Announcement - StocksToTrade
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Candel Therapeutics files for offering of 18.3 mln shares of common stock - marketscreener.com
Candel Therapeutics Files For Offering Of 18.3 Mln Shares Of Common Stock - TradingView
Should I hold or sell Candel Therapeutics Inc. nowJuly 2025 Action & Risk Controlled Swing Alerts - mfd.ru
Latham & Watkins Advises RTW Investments on US$100 Million Royalty Funding Agreement With Candel Therapeutics - Latham & Watkins LLP
Key facts: Candel Therapeutics secures $100M funding; plans drug launches - TradingView
Small cap wrap: EnWave, Nextech3D.ai, Candel Therapeutics, EDM Resources… - Proactive financial news
Candel Therapeutics Initiates $100M Stock Offering Amid Market Fluctuations - StocksToTrade
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Stock market today: Dow Jones, S&P 500 futures rise ahead of Q4 GDP numbers—Grail, Candel Therapeutics, Copart in focus - MSN
Candel Therapeutics stock falls on $100 million offering pricing By Investing.com - Investing.com Canada
Candel Therapeutics stock falls on $100 million offering pricing - Investing.com
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):